Comparative Pharmacology
Head-to-head clinical analysis: REXULTI versus RISVAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: REXULTI versus RISVAN.
REXULTI vs RISVAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Partial agonist at D2 and 5-HT1A receptors; antagonist at 5-HT2A and α1B/α2C adrenergic receptors.
Risperidone is an atypical antipsychotic that acts as a serotonin 5-HT2A and dopamine D2 receptor antagonist. It also binds to alpha1-adrenergic and H1 histaminergic receptors.
2 mg orally once daily initially; increase to 4 mg once daily no sooner than week 2; target dose 4 mg once daily; range 2-4 mg once daily.
70 mg orally once daily, with or without food.
None Documented
None Documented
Terminal elimination half-life is approximately 19–23 days for brexpiprazole and its major metabolite DM-3411, requiring up to 2–3 months to reach steady state.
Terminal elimination half-life: 12-15 hours in healthy adults; prolonged to 20-30 hours in hepatic impairment (Child-Pugh B/C).
Approximately 25% of the dose is excreted in urine as unchanged drug and metabolites; about 54% is excreted in feces. Renal excretion of unchanged drug is minor (<1%).
Renal: 30% unchanged; Fecal: 65% (biliary excretion of metabolites); 5% other.
Category C
Category C
Atypical Antipsychotic
Atypical Antipsychotic